Pscilly

UCSF Psychedelic Study CANOPY Will Track 3,000 Real-World Users

By · Published

Most of what science knows about psilocybin and other psychedelics comes from tightly controlled clinical rooms. A new project at UC San Francisco is built to study the far more common setting: people's homes, retreats and ceremonies, where the vast majority of psychedelic experiences actually happen.

The study, called CANOPY, aims to enroll as many as 3,000 adults around the world who have already made their own plans to take a psychedelic. Researchers will track how those experiences relate to mood, well-being and other psychological measures, starting before the session and continuing for up to six months afterward.

The effort is led by Robin Carhart-Harris, a UCSF professor of neurology and one of the best-known figures in modern psilocybin research. He has said the goal is to bring scientific rigor to real-world use at a scale researchers have not had before, and to learn not only whether psychedelics can help, but for whom, in what circumstances and why.

How the study works

CANOPY is observational, not a drug trial. UCSF has stated plainly that it does not provide psychedelics, does not tell participants what to take and does not direct anyone to obtain or use them. Enrollment is limited to adults over 18 who were already planning a psychedelic experience and are willing to complete research questionnaires.

Most participation happens remotely through standardized assessments. According to the study's consent materials, researchers want to understand why participants chose to take a psychedelic, what they intended, what kind of environment they were in, how they felt beforehand, what the experience was like and what changes appeared afterward.

A smaller group who can travel to the UCSF campus in San Francisco will go further. Those volunteers will have brain imaging and EEG recordings, give blood and saliva samples before their planned experience and wear devices that collect physiological data outside the lab.

The substances covered are broad: psilocybin, LSD, ayahuasca and ibogaine, along with MDMA and ketamine. The researchers say they want to separate the effects of the drug itself from the personal, biological, psychological and environmental factors that seem to push some experiences toward lasting benefit and others toward harm.

Part of a larger federal bet

CANOPY received an award of up to $1.4 million from the Advanced Research Projects Agency for Health, or ARPA-H, an agency within the U.S. Department of Health and Human Services. It is one of three UCSF psychedelic projects that together received up to $8.5 million from the agency.

Carhart-Harris also co-leads a separate study of up to $4 million with Jennifer Mitchell that will look at how mindset and surroundings shape psychedelic effects. A third project, co-led by Mitchell and Lorenzo Pasquini, received up to $3.1 million to study psychedelics in older adults with low well-being and biomarkers linked to preclinical Alzheimer's disease.

The funding lands during an unusually active stretch for federal psychedelic policy, with health officials backing new psilocybin and ibogaine research and a House hearing on psychedelic therapy for veterans scheduled this week.

What it means in California

The Bay Area already anchors much of the country's psychedelic science. Across the bay, the UC Berkeley Center for the Science of Psychedelics runs its own research and education programs, and San Francisco's California Institute of Integral Studies Ketamine-Assisted Psychotherapy Clinic works in the related field of ketamine therapy. Further south, The Lundquist Institute Psilocybin Therapy Trial is among the clinical studies testing psilocybin under medical supervision. None of these groups is part of CANOPY.

It is important to be clear about the law. Psilocybin remains a Schedule I controlled substance under federal law and is not legal for personal use in California. An observational study does not change that, and taking part does not provide any legal protection. Anyone weighing a psychedelic for a health reason should talk with a licensed medical professional first.

UCSF says the data gathered through CANOPY will serve as a platform for more targeted research and help inform future clinical trials, along with a clearer picture of the risks and benefits of psychedelic use outside controlled settings.

ARPA-H awards to UCSF psychedelic projects
Mindset and setting study4 $ millions (up to)
Older adults / preclinical Alzheimer's3.1 $ millions (up to)
CANOPY real-world study1.4 $ millions (up to)

Maximum award amounts for three UCSF psychedelic research projects, as announced by UCSF; total up to $8.5 million.

On Pscilly

Published
November 16, 2026
Place
San Francisco, CA

Nearby